Vifor's Venofer re-analysis reveals high-dose benefit in hemodialysis

22 January 2019

Swiss drugmaker Vifor Pharma (VTX: VIFN) has clarified what it calls a ‘programming error’ in the original analysis by the investigators in the PIVOTAL trial.

The re-analysis of the data has revealed a statistically-significant improvement in the treatment effects of a higher dose of Venofer (intravenous iron sucrose) compared with a lower dose of the drug, which is the leading intravenous iron brand, in terms of volume usage, worldwide.

These results in hemodialysis patients, showing a significant reduction in the risk of death or major cardiovascular events with the higher dose, supersede those presented in October.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK